FDA Expands Use of Botox and Dysport for Spasticity in Pediatric Patients
The FDA has approved the expanded use of Botox® (onabotulinumtoxinA; Allergan) for the treatment of spasticity in pediatric patients aged ≥2 years, including those with lower limb spasticity caused by cerebral palsy.